Lipoprotein-associated phospholipase A2: A target directed at the atherosclerotic plaque

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 3, 2002, Pages 309-314

  Suckling, Keith E ^a   Macphee, Colin H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Atherosclerosis; Atherosclerotic plaque; C reactive protein; Inhibitors; Lysophosphatidylcholine; Phospholipase; Plate activating factor acetylhydrolase; WOSCOPS

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; FATTY ACID; FIBRINOGEN; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PADGEM PROTEIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPID;

ANGIOCARDIOGRAPHY; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE MARKER; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FATTY ACID OXIDATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID HYDROLYSIS; LIPID OXIDATION; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MACROPHAGES; MIDDLE AGED; PHOSPHOLIPASES A; RABBITS; VASCULAR DISEASES;

EID: 0036075532     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.3.309     Document Type: Review

References (39)

1. The evolving role of statins in the management of atherosclerosis
2. Oxidized LDL bind to nonproteoglycan components of smooth muscle extracellular matrices
3. Role of oxidised LDL in atherosclerosis
4. Lipoprotein lipase in the arterial wall: Linking LDL to the arterial extracellular matrix and much more
5. The role of plaque rupture and thrombosis in coronary artery disease
6. Atherosclerosis - An inflammatory disease
7. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma
8. Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor
9. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions
10. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor
11. Inhibition of lipoprotein-associated phospholipase A(2) diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages
12. Signaling mechanism underlying COX-2 induction by lysophosphatidylcholine
13. Lysophosphatidylcholine and reactive oxygen species mediate the synergistic effect of mildly oxidized LDL with serotonin on vascular smooth muscle cell proliferation
14. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells
15. Involvement of oxysterols and lysophosphatidylcholine in the oxidized LDL-induced impairment of serum albumin synthesis by HEPG2 cells
16. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells
17. Oxidized LDL and expression of monocyte adhesion molecules
18. Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-related kinase pathway
19. Burst production of superoxide anion in human endothelial cells by lysophosphatidylcholine
20. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins
21. 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A(2)
22. N-1 substituted pyrimidin-4-ones: Novel, orally active inhibitors of lipoprotein-associated phospholipase A(2)
23. Anti-atherosclerotic effect of SB-244323, a lipoprotein-associated phospholipase A2 inhibitor in WHHL rabbits
24. Lipoprotein-associated phospholipase A (2), platelet-activating factor acetylhydrolase: A potential new risk factor for coronary artery disease
25. Lipoprotein-associated phospholipase A(2) as an independent predictor of coronary heart disease
26. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women
27. 2: An emerging biomarker of coronary heart disease
28. The expanding superfamily of phospholipase A(2) enzymes: Classification and characterization
29. Phospholipase A(2) in vascular disease
30. Phospholipase A(2) and small, dense low-density lipoprotein
31. Platelet-activating factor and related lipid mediators
32. Clinical trials: Surrogate endpoints or hard endpoints?
33. Novel risk factors for systemic atherosclerosis - A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease
34. High-sensitivity C-reactive protein - Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
35. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease
36. Soluble P-selectin and the risk of future cardiovascular events
37. The human high-risk plaque and its detection by magnetic resonance imaging
38. Characterization of atherosclerotic plaque by magnetic resonance imaging
39. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease